Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Cash (2016 - 2025)

Integra Lifesciences Holdings' Change in Cash history spans 17 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 90.83% year-over-year to $2.9 million; the TTM value through Dec 2025 reached -$11.3 million, up 62.28%, while the annual FY2025 figure was -$11.3 million, 62.28% up from the prior year.
  • Change in Cash for Q4 2025 was $2.9 million at Integra Lifesciences Holdings, down from $14.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $315.5 million in Q1 2024 and bottomed at -$376.7 million in Q2 2024.
  • The 5-year median for Change in Cash is $873000.0 (2023), against an average of -$11.8 million.
  • The largest annual shift saw Change in Cash crashed 20739.45% in 2024 before it surged 18165.82% in 2025.
  • A 5-year view of Change in Cash shows it stood at $43.2 million in 2021, then tumbled by 227.9% to -$55.3 million in 2022, then skyrocketed by 104.83% to $2.7 million in 2023, then surged by 1069.21% to $31.2 million in 2024, then tumbled by 90.83% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Change in Cash are $2.9 million (Q4 2025), $14.3 million (Q3 2025), and -$21.2 million (Q2 2025).